tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jun 14;10(6):944.
doi: 10.3390/vaccines10060944.
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
Ramireddy Bommireddy[SUP] 1 [/SUP], Shannon Stone[SUP] 2 [/SUP], Noopur Bhatnagar[SUP] 3 [/SUP], Pratima Kumari[SUP] 2 [/SUP], Luis E Munoz[SUP] 1 [/SUP], Judy Oh[SUP] 3 [/SUP], Ki-Hye Kim[SUP] 3 [/SUP], Jameson T L Berry[SUP] 1 [/SUP], Kristen M Jacobsen[SUP] 4 [/SUP], Lahcen Jaafar[SUP] 4 [/SUP], Swe-Htet Naing[SUP] 4 [/SUP], Allison N Blackerby[SUP] 4 [/SUP], Tori Van der Gaag[SUP] 4 [/SUP], Chloe N Wright[SUP] 4 [/SUP], Lilin Lai[SUP] 5 [/SUP], Christopher D Pack[SUP] 4 [/SUP], Sampath Ramachandiran[SUP] 4 [/SUP], Mehul S Suthar[SUP] 5 [/SUP], Sang-Moo Kang[SUP] 3 [/SUP], Mukesh Kumar[SUP] 2 [/SUP], Shaker J C Reddy[SUP] 4 [/SUP], Periasamy Selvaraj[SUP] 1 [/SUP]
Affiliations
Abstract
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.
Keywords: GM-CSF; IL-12; RBD; SARS-CoV-2; antibodies; influenza; mice; virus-like particles.
. 2022 Jun 14;10(6):944.
doi: 10.3390/vaccines10060944.
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
Ramireddy Bommireddy[SUP] 1 [/SUP], Shannon Stone[SUP] 2 [/SUP], Noopur Bhatnagar[SUP] 3 [/SUP], Pratima Kumari[SUP] 2 [/SUP], Luis E Munoz[SUP] 1 [/SUP], Judy Oh[SUP] 3 [/SUP], Ki-Hye Kim[SUP] 3 [/SUP], Jameson T L Berry[SUP] 1 [/SUP], Kristen M Jacobsen[SUP] 4 [/SUP], Lahcen Jaafar[SUP] 4 [/SUP], Swe-Htet Naing[SUP] 4 [/SUP], Allison N Blackerby[SUP] 4 [/SUP], Tori Van der Gaag[SUP] 4 [/SUP], Chloe N Wright[SUP] 4 [/SUP], Lilin Lai[SUP] 5 [/SUP], Christopher D Pack[SUP] 4 [/SUP], Sampath Ramachandiran[SUP] 4 [/SUP], Mehul S Suthar[SUP] 5 [/SUP], Sang-Moo Kang[SUP] 3 [/SUP], Mukesh Kumar[SUP] 2 [/SUP], Shaker J C Reddy[SUP] 4 [/SUP], Periasamy Selvaraj[SUP] 1 [/SUP]
Affiliations
- PMID: 35746552
- DOI: 10.3390/vaccines10060944
Abstract
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.
Keywords: GM-CSF; IL-12; RBD; SARS-CoV-2; antibodies; influenza; mice; virus-like particles.